Vanguard Group Inc. Sells 121,644 Shares of STAAR Surgical Company $STAA

Vanguard Group Inc. lessened its holdings in shares of STAAR Surgical Company (NASDAQ:STAA) by 2.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,269,123 shares of the medical instruments supplier’s stock after selling 121,644 shares during the quarter. Vanguard Group Inc. owned 0.09% of STAAR Surgical worth $114,711,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Broadwood Capital Inc. lifted its position in STAAR Surgical by 8.5% in the 2nd quarter. Broadwood Capital Inc. now owns 13,519,491 shares of the medical instruments supplier’s stock valued at $226,857,000 after acquiring an additional 1,064,227 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in STAAR Surgical by 16.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier’s stock valued at $50,084,000 after acquiring an additional 421,840 shares in the last quarter. Resona Asset Management Co. Ltd. grew its position in STAAR Surgical by 11.6% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 2,421,836 shares of the medical instruments supplier’s stock worth $40,746,000 after purchasing an additional 252,218 shares in the last quarter. Yunqi Capital Ltd boosted its stake in shares of STAAR Surgical by 24.4% in the 2nd quarter. Yunqi Capital Ltd now owns 2,411,288 shares of the medical instruments supplier’s stock worth $40,461,000 after buying an additional 473,699 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of STAAR Surgical by 0.3% during the second quarter. Geode Capital Management LLC now owns 1,192,821 shares of the medical instruments supplier’s stock valued at $20,018,000 after acquiring an additional 3,335 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. bought 336,946 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were acquired at an average price of $21.62 per share, with a total value of $7,284,772.52. Following the acquisition, the insider owned 15,356,437 shares of the company’s stock, valued at approximately $332,006,167.94. The trade was a 2.24% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders have purchased 434,138 shares of company stock valued at $9,424,176 in the last three months. 0.59% of the stock is currently owned by company insiders.

STAAR Surgical Trading Up 1.6%

STAA opened at $19.22 on Thursday. STAAR Surgical Company has a 12 month low of $14.69 and a 12 month high of $30.81. The company has a market cap of $956.00 million, a PE ratio of -11.79 and a beta of 1.05. The company has a 50 day moving average of $19.88 and a 200 day moving average of $24.15.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.51). The company had revenue of $57.80 million during the quarter, compared to analysts’ expectations of $75.54 million. STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.01%. The company’s revenue was up 18.0% compared to the same quarter last year. Research analysts forecast that STAAR Surgical Company will post -1.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

STAA has been the topic of a number of research analyst reports. Morgan Stanley started coverage on shares of STAAR Surgical in a report on Friday, January 16th. They issued an “underweight” rating and a $13.00 price target on the stock. BTIG Research restated a “neutral” rating on shares of STAAR Surgical in a research note on Tuesday, January 6th. Wells Fargo & Company upped their price objective on STAAR Surgical from $28.00 to $30.75 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Weiss Ratings reissued a “sell (d)” rating on shares of STAAR Surgical in a report on Thursday, January 22nd. Finally, Jefferies Financial Group lowered their target price on STAAR Surgical from $28.00 to $21.50 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $20.78.

Key STAAR Surgical News

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Management said it is targeting a return to profitability in 2026 after a volatile 2025, giving investors a recovery path to model. STAAR Surgical Eyes 2026 Profit
• Positive Sentiment: Geographic strength — especially strong sales growth in China — helped total revenue rise ~18% year‑over‑year, signaling demand resilience for EVO ICL products. Q4 Highlights: China Growth
• Positive Sentiment: Gross margins expanded as cost of sales declined and the company finished the quarter with a solid cash balance (~$153M), which supports the recovery plan. Q4 Financial Details
• Neutral Sentiment: Analysts remain mixed: Needham maintained a Hold (neutral) view, reflecting short‑term revenue headwinds but belief in a 2026 recovery. Needham Hold Rating
• Neutral Sentiment: Company issued a shareholder letter and held an earnings call/transcript that provide more detail on near‑term actions and leadership transition — useful for modeling timing of the turnaround. Shareholder Letter Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: revenue of $57.8M fell well short of Street estimates and the company reported a net loss and operating loss, with diluted EPS near -$0.37 — this is the primary reason for the sell‑reaction. Q4 Results & Miss
• Negative Sentiment: Stifel cut its price target to $18 and moved to a Hold after the “noisy” Q4 print, signaling reduced near‑term upside and increased analyst caution. Stifel PT Cut
• Negative Sentiment: Despite y/y revenue growth, operating loss widened and EPS missed consensus, creating near‑term execution risk until the company demonstrates consistent top‑line recovery. Earnings Miss Coverage

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.